Key facts
- Status: Privately Held (backing).
- ·Watchlist + deal alerts for EQGen Biomedical
- ·The full record, as it builds
Funding rounds
No funding rounds for EQGen Biomedical are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About EQGen Biomedical
Developer of veterinary regenerative stem cell therapies designed to treat osteoarthritis and other degenerative joint diseases in animals. The company offers a proprietary platform technology that purifies pluripotent stem cell populations for intra-articular use, enabling equine, canine, and camelid veterinarians to access safe and effective disease-modifying treatments.
- Sector
- Healthcare
- HQ
- Boston, MA, United States
- Founded
- 2024
- Employees
- 3
- Website
- eqgenbiomed.com/
- Ownership
- Privately Held (backing)
EQGen Biomedical doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in EQGen Biomedical shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on EQGen Biomedical in its N-PORT filings yet. We sweep new filings monthly.